IP Library Granted Patent US 8,507,211
Granted Patent B2
US 8,507,211 · App. 13/489,621 · Granted Aug 13, 2013

Tuberculosis diagnostic test

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,507,211
App. No.
13/489,621
Granted
Aug 13, 2013
Kind
B2
Abstract

A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided.

Claims (22)

1. A method of in vitro diagnosis of Mycobacterium tuberculosis infection in a host, comprising

(a) keeping a population of T cells isolated from said host in contact with a peptide panel comprising one or more epitopes contained within peptide SEQ ID NO: 1, and

(b) detecting a recognition response by the T cells to the peptide panel.

2. The method of claim 1 , wherein the peptide panel further comprises one or more epitopes contained within one or more peptides selected from the group consisting of: peptide SEQ ID NO: 2, peptide SEQ ID NO: 3, peptide SEQ ID NO: 4, peptide SEQ ID NO: 5, peptide SEQ ID NO: 6, peptide SEQ ID NO: 7, peptide SEQ ID NO: 8, peptide SEQ ID NO: 9, peptide SEQ ID NO: 10 and peptide SEQ ID NO: 11.

3. The method of claim 1 , wherein the method yields a diagnostic sensitivity of at least 50%.

4. The method of claim 1 , wherein the T cells are incubated with the peptide panel for between 4 and 24 hours prior to determining the recognition response.

5. The method of claim 1 , wherein the T cells are freshly isolated.

6. The method of claim 1 , wherein the T cells are isolated from blood.

7. The method of claim 1 , wherein the T cells comprise CD4+ and CD8+ T cells.

8. The method of claim 1 , wherein the T cells comprise CD4+ immediate effector T cells.

9. The method of claim 1 , wherein the recognition response is measured by detecting IFNγ secretion from the T cells.

10. The method of claim 2 , wherein the method yields a diagnostic sensitivity of at least 50%.

11. The method of claim 2 , wherein the T cells are incubated with the peptide panel for between 4 and 24 hours prior to determining the recognition response.

12. The method of claim 2 , wherein the T cells are freshly isolated.

13. The method of claim 2 , wherein the T cells are isolated from blood.

14. The method of claim 2 , wherein the T cells comprise CD4+ and CD8+ T cells.

15. The method of claim 2 , wherein the T cells comprise CD4+ immediate effector T cells.

16. The method of claim 2 , wherein the recognition response is measured by detecting IFNγ secretion from the T cells.

17. A method of in vitro diagnosis of Mycobacterium tuberculosis infection in a host, comprising

(a) keeping a population of T cells isolated from said host in contact with a peptide panel comprising peptide SEQ ID NO: 1, peptide SEQ ID NO: 2, peptide SEQ ID NO: 3, peptide SEQ ID NO: 4, peptide SEQ ID NO: 5, peptide SEQ ID NO: 6, peptide SEQ ID NO: 7, and peptide SEQ ID NO: 8; and

(b) detecting a recognition response by the T cells to the peptide panel.

18. The method of claim 17 , wherein the peptide panel further comprises one or more peptides selected from the group consisting of peptide SEQ ID NO: 9, peptide SEQ ID NO: 10 and peptide SEQ ID NO: 11.

Assignments (8)
RELEASE OF SECURITY INTEREST (TERM) Recorded Nov 7, 2018
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OXFORD IMMUNOTEC, INC.; OXFORD IMMUNOTEC GLOBAL PLC; OXFORD IMMUNOTEC LIMITED; IMMUNETICS, INC.
Reel/Frame 047445/0487 →
RELEASE OF SECURITY INTEREST (REVOLVING) Recorded Nov 7, 2018
From: MIDCAP FUNDING IV TRUST, AS SUCCESSOR TO MIDCAP FINANCIAL TRUST
To: OXFORD IMMUNOTEC, INC.; OXFORD IMMUNOTEC GLOBAL PLC; OXFORD IMMUNOTEC LIMITED; IMMUNETICS, INC.
Reel/Frame 047890/0001 →
SECURITY INTEREST (REVOLVING LOAN) Recorded Oct 5, 2016
From: OXFORD IMMUNOTEC, INC.; OXFORD IMMUNOTEC GLOBAL PLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040227/0257 →
SECURITY INTEREST (TERM LOAN) Recorded Oct 5, 2016
From: OXFORD IMMUNOTEC, INC.; OXFORD IMMUNOTEC GLOBAL PLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040228/0887 →
CHANGE OF NAME Recorded Aug 2, 2016
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 039550/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2014
From: ISIS INNOVATION LIMITED
To: OXFORD IMMUNOTEC LIMITED
Reel/Frame 032945/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2014
From: LALVANI, AJIT; PATHAN, ANSAR A.
To: ISIS INNOVATION LIMITED
Reel/Frame 032192/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2014
From: ISIS INNOVATION LIMITED
To: OXFORD IMMUNOTEC LIMITED
Reel/Frame 032191/0698 →